menu
    • menu
    [{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Lyndra Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Lyndra Therapeutics"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Aig Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Aig Investments","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Aig Investments"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sarissa Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series E Financing","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sarissa Capital","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sarissa Capital"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Lyndra Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LYN-057","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Rsv Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Lyndra Therapeutics

    Menu

    Lyndra Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With...

                            Details : Risperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Thermo Fisher Scientific

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lyndra, Thermo Fisher Partner on Long-Acting Oral Therapy Development

                            Details : The collaboration aims to advance the Lynra late-stage product LYN-005 (risperidone), which is being evaluated for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 15, 2025

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Thermo Fisher Scientific

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyndra Therapeutics Announces Positive Data from Phase 3 Study of Weekly Oral Risperidone

                            Details : LYN-005 (oral weekly risperidone), is being evaluated in phase 3 clinical trials for the treatment of people living with schizophrenia and bipolar 1 disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2024

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Sun Pharma to Acquire 16.7% Stake in Lyndra Therapeutics for $30 mn

                            Details : The financing will obtain access to technology for certain compounds while developing novel pharmaceutical delivery systems, including LYN-005 (risperidone) for schizophrenia and bipolar I disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 02, 2024

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Sarissa Capital

                            Deal Size : $101.0 million

                            Deal Type : Series E Financing

                            DEALS_DEV arrow-down

                            Lyndra Therapeutics Raises US$101 Million in Series E Funding

                            Details : The net proceeds will support the development of Lyndra’s pipeline, including oral weekly LYN-005 (risperidone), which is near completion of a pivotal phase 3 study and is being developed for the treatment of people living with schizophrenia and bipola...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 25, 2023

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Sarissa Capital

                            Deal Size : $101.0 million

                            Deal Type : Series E Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-00...

                            Details : Oral weekly LYN-005 (risperidone) is a serotonin and norepinephrine reuptake inhibitor and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 09, 2023

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYN-005

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

                            Details : LYN-005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 22, 2023

                            Lead Product(s) : LYN-005

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a...

                            Details : Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levomethadone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

                            Details : Levomethadone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opioid-Related Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2022

                            Lead Product(s) : Levomethadone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levomethadone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyndra’s Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014

                            Details : LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 27, 2021

                            Lead Product(s) : Levomethadone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth